NanoString Technologies Inc. (NSTG) and ImmunoCellular Therapeutics Ltd. (OTCMKTS:IMUC) Contrasting side by side

Both NanoString Technologies Inc. (NASDAQ:NSTG) and ImmunoCellular Therapeutics Ltd. (OTCMKTS:IMUC) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to analyst recommendations, profitability, risk, dividends, institutional ownership, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
NanoString Technologies Inc. 111.33M 8.17 80.10M -2.80 0.00
ImmunoCellular Therapeutics Ltd. N/A 0.00 9.03M -0.48 0.00

Table 1 shows the gross revenue, earnings per share (EPS) and valuation for NanoString Technologies Inc. and ImmunoCellular Therapeutics Ltd.


Table 2 shows us the return on assets, return on equity and net margins of both companies.

Net Margins Return on Equity Return on Assets
NanoString Technologies Inc. -71.95% -212.2% -49.8%
ImmunoCellular Therapeutics Ltd. 0.00% -321.9% -158.6%

Risk & Volatility

A 1.29 beta indicates that NanoString Technologies Inc. is 29.00% more volatile compared to S&P 500. Competitively, ImmunoCellular Therapeutics Ltd. is 131.00% less volatile than S&P 500, because of the -0.31 beta.


The Current Ratio and Quick Ratio of NanoString Technologies Inc. are 3.1 and 2.7 respectively. Its competitor ImmunoCellular Therapeutics Ltd.’s Current Ratio is 9.5 and its Quick Ratio is 9.5. ImmunoCellular Therapeutics Ltd. can pay off short and long-term obligations better than NanoString Technologies Inc.

Analyst Ratings

The following table shown below contains the ratings and recommendations for NanoString Technologies Inc. and ImmunoCellular Therapeutics Ltd.

Sell Ratings Hold Ratings Buy Ratings Rating Score
NanoString Technologies Inc. 0 1 2 2.67
ImmunoCellular Therapeutics Ltd. 0 0 0 0.00

NanoString Technologies Inc. has a 11.80% upside potential and an average target price of $29.

Institutional & Insider Ownership

NanoString Technologies Inc. and ImmunoCellular Therapeutics Ltd. has shares owned by institutional investors as follows: 80.6% and 4.3%. NanoString Technologies Inc.’s share owned by insiders are 0.6%. Competitively, 0.3% are ImmunoCellular Therapeutics Ltd.’s share owned by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
NanoString Technologies Inc. 2.53% 11.46% 21.69% 75.44% 151.12% 88.81%
ImmunoCellular Therapeutics Ltd. -18.15% -21.62% -21.77% -36.31% -92.54% 19.88%

For the past year NanoString Technologies Inc. was more bullish than ImmunoCellular Therapeutics Ltd.


NanoString Technologies Inc. beats ImmunoCellular Therapeutics Ltd. on 6 of the 10 factors.

NanoString Technologies, Inc. develops, manufactures, and sells life science tools for translational research and molecular diagnostic products worldwide. The company offers nCounter Analysis System, an automated, multi-application, digital detection, and counting system. It provides nCounter MAX and FLEX systems that include nCounter Prep Station, an automated liquid handling component that processes and prepares samples for data collection; and nCounter Digital Analyzer, which collects data from samples through the images of the immobilized fluorescent reporters in the sample cartridge and processing the data into output files. The company also offers nCounter SPRINT Profiler, an instrument that provides liquid handling steps and the digital analysis through use of a microfluidic cartridge; and nSolver Analysis Software, a data analysis program that enables researchers to check, normalize, and analyze their data. In addition, it provides custom CodeSets; and Pan Cancer pathways gene expression panels, including pathways, immune profiling, and progression panels, as well as nCounter Vantage 3D, other gene expression, miRNA expression, and cancer copy number variation panels. Further, the company offers nCounter Elements reagents that allow users to design customized assays for gene expression, copy number variation, and gene fusions; Master Kits, which include ancillary reagents and plasticware to setup and process samples in the nCounter Prep Station and nCounter Digital Analyzer; and nCounter Dx Analysis System and Prosigna molecular diagnostic test kits. It markets its systems and related consumables to researchers in academic, government, and biopharmaceutical laboratories, as well as to clinical laboratories and medical centers. NanoString Technologies, Inc. has collaboration with Celgene Corporation; Merck Sharp & Dohme Corp.; Medivation, Inc.; and Astellas Pharma, Inc. The company was founded in 2003 and is headquartered in Seattle, Washington.

ImmunoCellular Therapeutics, Ltd., a clinical-stage biotechnology company, develops immune-based therapies for the treatment of various cancers. Its lead product candidate is ICT-107, a dendritic cell (DC) immunotherapy targeting cancer stem cells (CSCs) and cancer antigens, which is in Phase III clinical trials for the treatment of glioblastoma multiforme (GBM). The company is also developing ICT-140, a DC-based immunotherapy targeting CSCs and cancer antigens that is in Phase I clinical trials for the treatment of ovarian cancer; and ICT-121, a DC-based immunotherapy targeting CD133 markers and CSCs, which is in Phase I clinical trials to treat recurrent GBM and other solid tumor cancers. In addition, it has a portfolio of other potential therapeutic immunotherapies to treat cancer. The company was formerly known as Optical Molecular Imaging, Inc. and changed its name to ImmunoCellular Therapeutics, Ltd. in November 2006. ImmunoCellular Therapeutics, Ltd. is based in Calabasas, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.